Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Emergent BioSolutions Inc. is a U.S.-based biopharmaceutical company focused on developing, manufacturing, and commercializing medical countermeasures and specialty products addressing public health threats. The company operates primarily within the biodefense, infectious disease, and public health preparedness sectors, serving government agencies, healthcare providers, and institutional customers. Its business model is heavily oriented toward contracts and long-term procurement agreements with government entities, particularly for stockpiled medical countermeasures.
The company’s primary revenue drivers include medical countermeasure products, vaccines, and contract development and manufacturing services. Emergent has positioned itself as one of a limited number of suppliers capable of large-scale production of specialized biologics for national preparedness programs. Founded in 1998, the company initially focused on biodefense vaccines and expanded through acquisitions into contract manufacturing and broader life sciences services, significantly reshaping its portfolio during the 2010s and early 2020s.
Business Operations
Emergent operates through several core business segments encompassing Commercial Products, Medical Countermeasures, and Services. Its product portfolio includes vaccines, therapeutics, and treatments targeting anthrax, smallpox, opioid overdose, and other public health emergencies. Revenue is generated through product sales, government procurement contracts, and manufacturing services for third-party pharmaceutical and biotechnology companies.
The company maintains both domestic and international operations, with manufacturing and development facilities primarily in the United States and Canada. Emergent controls specialized biologics manufacturing assets, including large-scale vaccine production capabilities and biosafety-level facilities. Its services business has included contract development and manufacturing (CDMO) offerings through subsidiaries such as Emergent BioSolutions Manufacturing, supporting external clients across clinical and commercial stages.
Strategic Position & Investments
Emergent’s strategic direction has emphasized refocusing on core medical countermeasure and public health products while rationalizing its asset base following operational and financial challenges related to COVID-19 vaccine manufacturing. The company has pursued divestitures of non-core assets and restructuring initiatives to strengthen liquidity and operational efficiency, while continuing to invest in priority biodefense products supported by U.S. government funding.
Notable investments and acquisitions historically include the purchase of PaxVax, Adapt Pharma, and Valortim, which expanded Emergent’s vaccine, opioid overdose, and anthrax treatment portfolios. The company continues to be involved in emerging areas related to biodefense innovation, advanced manufacturing technologies, and next-generation vaccines, though some development programs have been paused or reassessed based on strategic and financial considerations.
Geographic Footprint
Emergent BioSolutions is headquartered in Gaithersburg, Maryland, with a primary operational footprint across North America. Key facilities are located in Maryland, Michigan, Massachusetts, Ohio, and Winnipeg, Canada, supporting manufacturing, research, and administrative functions. These locations underpin the company’s role in supplying U.S. and allied government stockpiles.
Internationally, Emergent’s market presence is largely indirect, with products distributed to select global customers and governments through procurement programs rather than broad commercial retail channels. Its geographic influence is most pronounced in the United States, where federal agencies represent the largest customer base and strategic partner.
Leadership & Governance
Emergent was founded by Fuad El-Hibri, who played a central role in shaping its early biodefense focus. The company is governed by a board of directors overseeing strategic realignment and risk management following recent operational challenges. Leadership has emphasized operational discipline, compliance, and rebuilding trust with government stakeholders.
Key executives include:
- Joseph C. Papa – President and Chief Executive Officer
- Paul Williams – Senior Vice President, Products Business
- Gethin Jenkins – Executive Vice President and Chief Financial Officer
- Erika Wado – Executive Vice President, Legal Affairs and Compliance
- Kevin O’Neill – Senior Vice President, Manufacturing and Technical Operations
The leadership team’s stated strategic vision centers on stabilizing core operations, prioritizing high-value public health products, and strengthening governance and quality systems across the organization.